RIBOMIC Inc. announced that the first dose of RBM-007 (anti-FGF2 aptamer) was administered to a pediatric patient with Achondroplasia in the early phase II study to investigate the efficacy and safety of RBM-007. RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC's research facilities in Tokyo. RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.